Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2017 Dec 12

PMID 29226097

Citations 108

Authors

Jinlin Hou

Guiqiang Wang

Fusheng Wang

Jun Cheng

Hong Ren

Hui Zhuang

Jian Sun

Lanjuan Li

Jie Li

Qinghua Meng

Jingmin Zhao

Zhongping Duan

Jidong Jia

Hong Tang

Jifang Sheng

Jie Peng

Fengmin Lu

Qing Xie

Lai Wei

Affiliations

Soon will be listed here.

Citing Articles

The S267F variant of sodium taurocholate co-transporting polypeptide is strongly associated with resistance to chronic hepatitis B and high level of serum total bile acids.

Huang J, Su M, Chen H, Wu S, Chen Z Liver Res. 2025; 6(3):186-190.

PMID: 39958196 PMC: 11791793. DOI: 10.1016/j.livres.2022.08.005.

2024 latest report on hepatitis B virus epidemiology in China: current status, changing trajectory, and challenges.

Yan R, Sun M, Yang H, Du S, Sun L, Mao Y Hepatobiliary Surg Nutr. 2025; 14(1):66-77.

PMID: 39925891 PMC: 11806133. DOI: 10.21037/hbsn-2024-754.

Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective.

Gurjar S, Bhat A R, Upadhya R, Shenoy R Lipids Health Dis. 2025; 24(1):5.

PMID: 39773634 PMC: 11705780. DOI: 10.1186/s12944-024-02396-3.

Evaluation of genotype characteristics and drug resistance mutations in patients with chronic hepatitis B.

He C, Wu X, You Z, Zhou T, Diao L, Yang Y Sci Rep. 2024; 14(1):27575.

PMID: 39528567 PMC: 11555265. DOI: 10.1038/s41598-024-77362-1.

Prevalence of hepatitis B virus surface antigen, associated risk factors, and liver enzyme abnormalities among individuals with diabetes in Aksum town public hospitals, Tigray, northern Ethiopia.

Gebrelibanos M, Karri K, Abraha T, Gebreyesus H, Kidane H, Shfare M Pan Afr Med J. 2024; 49:6.

PMID: 39372697 PMC: 11453116. DOI: 10.11604/pamj.2024.49.6.43263.

References

Yin J, Li N, Han Y, Xue J, Deng Y, Shi J . Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013; 31(29):3647-55. DOI: 10.1200/JCO.2012.48.5896. View

Sarri G, Westby M, Bermingham S, Hill-Cawthorne G, Thomas H . Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance. BMJ. 2013; 346:f3893. DOI: 10.1136/bmj.f3893. View

Lai C, Yuen M . Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2012; 57(1):399-408. DOI: 10.1002/hep.25937. View

Kosi L, Reiberger T, Payer B, Grabmeier-Pfistershammer K, Strassl R, Rieger A . Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. J Viral Hepat. 2012; 19(11):801-10. DOI: 10.1111/j.1365-2893.2012.01601.x. View

Patterson S, George J, Strasser S, Lee A, Sievert W, Nicoll A . Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 2010; 60(2):247-54. DOI: 10.1136/gut.2010.223206. View

Yang Y, Shim J, Kim K, Lim Y, Lee H . Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology. 2013; 59(4):1303-10. DOI: 10.1002/hep.26910. View

Yao G, Zhu M, Cui Z, Wang B, Yao J, Zeng M . A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis. 2009; 10(2):131-7. DOI: 10.1111/j.1751-2980.2009.00375.x. View

McMahon B, Holck P, Bulkow L, Snowball M . Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001; 135(9):759-68. DOI: 10.7326/0003-4819-135-9-200111060-00006. View

Greenup A, Tan P, Nguyen V, Glass A, Davison S, Chatterjee U . Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014; 61(3):502-7. DOI: 10.1016/j.jhep.2014.04.038. View

10.

Pan C, Duan Z, Bhamidimarri K, Zou H, Liang X, Li J . An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2011; 10(5):452-9. DOI: 10.1016/j.cgh.2011.10.041. View

11.

Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S . Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol. 2013; 60(4):715-22. DOI: 10.1016/j.jhep.2013.11.024. View

12.

Hou F, Song L, Yuan Q, Fang L, Ge S, Zhang J . Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics. 2015; 5(3):218-26. PMC: 4279186. DOI: 10.7150/thno.10636. View

13.

Lampertico P, Vigano M, Di Costanzo G, Sagnelli E, Fasano M, Di Marco V . Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut. 2012; 62(2):290-8. DOI: 10.1136/gutjnl-2011-301430. View

14.

Liaw Y . Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009; 29 Suppl 1:100-7. DOI: 10.1111/j.1478-3231.2008.01941.x. View

15.

Chang T, Liaw Y, Wu S, Schiff E, Han K, Lai C . Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010; 52(3):886-93. DOI: 10.1002/hep.23785. View

16.

Marcellin P, Bonino F, Lau G, Farci P, Yurdaydin C, Piratvisuth T . Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009; 136(7):2169-2179.e1-4. DOI: 10.1053/j.gastro.2009.03.006. View

17.

Perrillo R, Gish R, Falck-Ytter Y . American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2014; 148(1):221-244.e3. DOI: 10.1053/j.gastro.2014.10.038. View

18.

Konstantinou D, Deutsch M . The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol. 2015; 28(2):221-228. PMC: 4367211. View

19.

Arvaniti V, DAmico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M . Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010; 139(4):1246-56, 1256.e1-5. DOI: 10.1053/j.gastro.2010.06.019. View

20.

Wang H, Chien M, Huang H, Chang H, Wu C, Chen P . Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol. 2010; 84(7):3454-63. PMC: 2838120. DOI: 10.1128/JVI.02164-09. View